Allogene’s cema-cel Achieves 58.3% MRD Clearance, Stock Rises 12.5%
Allogene Therapeutics reported a 58.3% MRD clearance rate for its cema-cel allogeneic CAR T therapy in the pivotal ALPHA3 LBCL trial, compared to a 16.7% rate in the control group. The therapy’s favorable safety profile enabling outpatient management drove a 12.5% stock surge and supported Citigroup’s Outperform rating.
1. ALPHA3 Trial Efficacy Results
The pivotal ALPHA3 trial evaluating cema-cel in Large B-cell Lymphoma patients reported a 58.3% MRD clearance rate among treated subjects, significantly outpacing the 16.7% clearance observed in the control group.
2. Safety Profile and Outpatient Management
Cema-cel showcased a favorable safety profile with no serious adverse events reported and all treatments administered in an outpatient setting, potentially lowering therapy costs and improving patient accessibility.
3. Stock Reaction and Analyst Rating
Following the trial data release, Allogene Therapeutics’ shares rose 12.5% to $3.06 on trading volume exceeding 86.6 million shares, while Citigroup maintained an Outperform rating based on the strong clinical performance.
4. Enrollment Timeline and Future Outlook
The company currently holds a market capitalization near $746 million and expects to complete ALPHA3 enrollment by the end of 2027, with pivotal data readouts anticipated in late 2027 and 2028.